GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'
Demonstrates effectiveness comparable to the global standard Oka strain vaccine YONGIN, South Korea, March 11, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that a...
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
Officially recognized by WHO as a standard varicella vaccine strain alongside Oka Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical...